Founded in 2015, LB Pharmaceuticals Inc, is committed to developing innovative therapies for neuropsychiatric diseases, including schizophrenia.

Our lead product candidate, LB-102, is a novel, patent-protected methylated derivative of amisulpride, designed to improve upon its therapeutic profile. Despite amisulpride’s favorable efficacy profile and extensive use outside the U.S., it was never approved in the U.S. for the treatment of schizophrenia. Our preclinical studies and Phase 1 clinical trials show potential to improve amisulpride on dosing, safety and potentially long-term efficacy. LB-102 is well-tolerated and achieved a level of dopamine receptor occupancy in the brain comparable to amisulpride at significantly lower doses. Currently, we are conducting a Phase 2 clinical trial in the U.S. to further assess LB-102’s safety and efficacy in treating acute schizophrenia. With a team of experienced professionals and a dedication to scientific excellence, we aim to transform the treatment landscape for neuropsychiatric disorders and enhance patient outcomes worldwide.

Our Goal: Nearly 50% of schizophrenia patients fail to respond adequately to existing therapies (limited efficacy and poor tolerability). ~74% of patients discontinue and cycle through multiple therapies within 18 months of starting treatment. We are dedicated to bringing LB-102 to the U.S. market to help treat patients suffering from schizophrenia and to add options for those who do not respond adequately to current antipsychotic medications. Our mission is to develop novel therapies that improve patient outcomes and address significant unmet medical needs in neuropsychiatric disorders.